TNFSF11 and Miyoshi myopathy: For the MM example with PMM  =  0.055/day, at the endpoint of simulation (corresponding to later stage III phase of MM), simulated concentrations of OPG, RANKL and IL-6 and MM-cell density increase 0.69-fold, 4.35-fold, 10-fold and 4.48-fold respectively, while clinical observations suggest that concentrations of OPG, RANKL and IL-6 and MM-cell density increase approximately 0.7-fold [38], [73], 4-fold [69], [70], 10-fold [75] and 5-fold respectively (Figure 5d).